Sign Up to like & get
recommendations!
1
Published in 2018 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofy210.2026
Abstract: Abstract Background Delafloxacin (DLX) is a broad-spectrum fluoroquinolone (FQ) antibacterial; approved in 2017 by the Food and Drug Administration for treatment of acute bacterial skin and skin structure infections (ABSSSIs). DLX is in clinical development…
read more here.
Keywords:
dlx;
research;
anaerobic isolates;
melinta therapeutics ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2018 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofy210.2030
Abstract: Abstract Background DLX, an anionic fluoroquinolone antibiotic with Gram-positive and Gram-negative activity, was recently approved for treatment of ABSSSI. Two global phase 3 ABSSSI trials (studies 302 and 303) included patients with cardiac or vascular…
read more here.
Keywords:
dlx;
melinta therapeutics;
treatment;
skin ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2024 at "Antibiotics"
DOI: 10.3390/antibiotics13070641
Abstract: High-level delafloxacin-resistant (H-L DLX-R) Staphylococcus aureus isolates (minimum inhibitory concentration ≥1 mg/L) associated with mutations affecting position 84 of ParC have emerged. We aimed to elucidate the role of these mutations as a mechanism of…
read more here.
Keywords:
parc;
resistance;
role;
dlx ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2021 at "Cancers"
DOI: 10.3390/cancers13123005
Abstract: Simple Summary DLX homeobox family genes encode transcription factors that have indispensable roles in embryonic and postnatal development. These genes are critically linked to the morphogenesis of craniofacial structures, branchial arches, forebrain, and sensory organs.…
read more here.
Keywords:
dlx;
dlx genes;
cancer;
dlx5 ... See more keywords